PEPTIDE CORTEXThe library
← The library

Melanotan II

researchSkin/Hair
Evidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposePigmentation / Sexual
MechanismMelanocortin agonist (experimental)
EffectsMelanocortin agonist (experimental)
DosingNo human dose established.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Protocols · as published3 sourced
Clinical trialErectile dysfunction crossover (Wessells, J Urol 1998, n=10)
RouteSubcutaneous
FrequencySingle doses (crossover)
Starting0.025 mg/kg SC
EscalationNone
Target0.025 mg/kg SC; erections in 8/10; "manageable side effects"
Clinical trialPilot phase 1 in 3 healthy men (Dorr, Life Sci 1996)
RouteSubcutaneous
FrequencyAlternate weekdays for 2 weeks
Starting0.01 mg/kg
Escalation0.005 mg/kg steps
Target0.025-0.03 mg/kg

Nausea, flushing and spontaneous erections were dose-limiting. Trial details via a secondary summary.

Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous
FrequencyLoading daily, then 1-2x weekly maintenance; bedtime
StartingDays 1-3: 100-250 mcg daily (tolerance test)
EscalationDays 4-14: 250-500 mcg daily; weeks 3-6: 500-1,000 mcg daily until target pigmentation
TargetMaintenance 500-1,000 mcg 1-2x weekly; light maintenance 250-500 mcg 1x weekly or less
CycleShort 4 weeks loading + 4+ weeks off; standard 6 + 4-6 off; "Most protocols cap loading at 8 weeks"

Never approved anywhere.

Batches on filenone

No tested batches on file.

Read with10
Cautions & interactions

Not FDA-approved; nausea, BP effects, hyperpigmentation; melanoma concern; avoid

BP effects possible; avoid with uncontrolled HTN; avoid if melanoma/skin cancer risk.

CV 1 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.